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(mOBJECTIVES This study sought to determine the relationship of KIM-1 levels with adverse clinical outcomes in acute
decompensated heart failure (ADHF).
BACKGROUND Kidney injury molecule (KIM)-1 is a biomarker expressed by the nephron in acute tubular injury, and is a
sensitive and speciﬁc marker for early acute kidney injury. Although commonly measured in urine, KIM-1 levels are also
detectable in plasma, but its clinical and prognostic utility in ADHF is unknown.
METHODS Baseline, 48- to 72-h, and 30-day KIM-1 plasma levels were measured in 874 subjects in the ASCEND-HF
(Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial. Multivariable logistic and Cox
models were used to assess the relationship between KIM-1 levels and outcomes during and after ADHF.
RESULTS The median circulating KIM-1 level at baseline was 375.4 pg/ml (interquartile range [IQR]: 237.0 to 633.1
pg/ml), at 48 to 72 h was 373.7 pg/ml (IQR: 220.3 to 640.5 pg/ml), and at 30 days was 382.6 pg/ml (IQR: 236.5 to 638.0
pg/ml). There were no associations between KIM-1 levels and any 30-day outcomes. In univariable analysis, both baseline
and follow-up KIM-1 were associated with greater 180-day mortality risk. However, after adjusting for blood urea ni-
trogen or creatinine in addition to established risk predictors from ASCEND-HF, higher KIM-1 at all time points during
hospitalization was not associated with in-hospital or post-discharge outcomes (all p > 0.05), but KIM-1 levels measured
at 30 days were associated independently with 180-day mortality (hazard ratio: 1.49; p ¼ 0.04).
CONCLUSIONS In our study cohort, circulating KIM-1 at baseline and during hospitalization was not associated
with adverse clinical outcomes in ADHF after adjusting for standard indices of kidney function.
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AND ACRONYMS
ADHF = acute decompensated
heart failure
IQR = interquartile range
KIM = kidney injury molecule
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778C ardio–renal interactions are com-mon in acute decompensated heartfailure (ADHF). Renal insufﬁciency
on presentation, or worsening renal function
during treatment, can lead to inadequate
decongestion, progressive decreasing renal
function, and adverse outcomes (1–3). As aresult, accurate measurement of renal function is
paramount for accurate diagnosis and treatment.
Renal function has classically been quantiﬁed by
endogenous markers of glomerular ﬁltration rate,
like serum creatinine and, more recently, cystatin C
(4,5). Both serum creatinine and cystatin C are pro-
gnostic for adverse outcomes in both acute and
chronic heart failure, yet these markers capture
little information about renal tubular injury in heart
failure (6–9).
Kidney injury molecule (KIM)-1 is an epithelial cell
adhesion glycoprotein that is up-regulated in the
proximal tubule epithelial cells and modulates the
regeneration and repair of a post-ischemic kidney
injury (10,11). Urinary KIM-1 may distinguish acute
tubular necrosis from other forms of acute renal
injury or chronic renal insufﬁciency (12,13).
Urinary KIM-1 levels have been suggested as a
valid biomarker of tubular injury in both acute and
chronic heart failure, where renal dysfunction is
common (14). Urinary KIM-1 levels are increased in
heart failure patients, and often parallel with clin-
ical severity; therefore, they may predict cardiorenal
syndrome, and may be associated with long-term
outcomes in chronic heart failure (15–18). However,
prospective measurement of plasma KIM-1 levels
in ADHF, as well as evaluating their response to
medical therapy and their impact on clinical out-
comes, has not been well-established. Because uri-
nary KIM-1 and plasma KIM-1 levels correlate, we
hypothesize that plasma KIM-1 will show similar
associations (19).
The ASCEND-HF (Acute Study of Clinical Eff-
ectiveness of Nesiritide in Decompensated Heart
Failure) biomarker substudy provides a unique op-
portunity to answer these questions (20). We aimed to
characterize the relationship of KIM-1 levels with
other indices of renal function and determine their
association with short-term renal outcomes. We also
sought to determine the impact of nesiritide on serial
KIM-1 levels, as well as its impact on intermediate- ands reported that he has no relationships relevant to the contents o
itor for this paper.
received March 13, 2015; revised manuscript received May 26, 2long-term clinical outcomes during and after hospi-
talization for ADHF.
METHODS
STUDY POPULATION. The ASCEND-HF trial was a
multicenter, randomized, double-blind, placebo-
controlled trial that assessed the effects of nesiritide,
a recombinant B-type natriuretic peptide with vaso-
dilating properties, in patients hospitalized with
ADHF. Patients were excluded if there was clinical
evidence for acute coronary syndrome or baseline
cardiac troponin >5 the upper reference limit, as
measured by the local clinical laboratory. The
design and primary results of ASCEND-HF have
been reported previously (20,21). Of the 7,411 pa-
tients randomly assigned, 904 were enrolled in the
biomarker substudy. These subjects had serial
venous blood sampling at baseline, at 48 to 72 h
after therapy initiation, and at a 30-day follow-
up visit (6,22). Blood samples were collected in
ethylenediaminetetraacetic acid–plasma, immedi-
ately centrifuged and stored at -80F for subsequent
analysis at a core laboratory.
KIM-1 MEASUREMENT. Circulating plasma KIM-1
levels were determined with single molecule count-
ing immunoassay technology, which has been des-
cribed previously (23). Brieﬂy, KIM-1 levels in 50-ml
plasma samples were quantiﬁed using a plate-based
sandwich immunoassay (capture antibody: Catalog
#AF1750 [R&D Systems, Minneapolis, Minnesota]
coated to a 96-well polystyrene assay plate; detection
antibody: Alexa-ﬂuor 647-labeled antibody Catalog
#AF1750 [R&D Systems]; standard curve: KIM-1 ana-
lyte Catalog #1750-TM [R&D Systems]). At the
completion of the assay, single molecules of detec-
tion antibody were counted on the Erenna System
(Singulex, Alameda, California). The reporting range
spanned 2 to 1,000 pg/ml, with an interassay coef-
ﬁcient of variation ranging from 9% to 15%. Samples
reporting results >1,000 pg/ml, were diluted 1:10
and retested to obtain a result within the assay
reporting range.
CLINICAL ENDPOINTS. The co-primary endpoints
from the ASCEND-HF trial were dyspnea improve-
ment (via 7-point Likert scale) at 6 to 24 h and
the composite endpoint of death or hospitalizationf this paper to disclose. John R. Teerlink, MD, served
015, accepted June 15, 2015.
TABLE 1 Baseline Characteristics
Baseline KIM-1 (pg/ml)
Total
(n ¼ 874) <278.3 278.3–526.7 >526.7 p Value*
Age (yrs) 67 (55–78) 62 (48–76) 71 (59–80) 67 (57–78) <0.0001
Sex (female) 31.6 27.8 30.1 37.1 0.016
Race (white) 67.7 65.3 70.9 68.7 0.37
Diabetes mellitus 46.0 28.5 44.2 65.0 <0.0001
Systolic BP (mm Hg) 125 (111–140) 123 (110–138) 122 (111–138) 128 (115–143) 0.019
Heart rate (beats/min) 79 (70–89) 82 (71–92) 77 (68–87) 77 (67–88) 0.0003
Atrial ﬁbrillation 41.4 35.7 46.2 44.0 0.044
Hypertension 78.2 75.6 77.1 82.1 0.056
BUN (mg/dl) 24 (17–35) 21 (15–28) 25 (18–35) 29 (21–43) <0.0001
Creatinine (mg/dl) 1.3 (1.03–1.7) 1.2 (1.0–1.44) 1.3 (1.04–1.7) 1.5 (1.12–2.0) <0.0001
Sodium (mmol/l) 139 (137–141) 139 (136–141) 139 (137–141) 139 (136–141) 0.73
NT-proBNP (pg/ml) (n ¼ 795) 5,773 (2,981–11,579) 4,442 (2,431–9,195) 6,399 (3,381–12,358) 7,011 (3,226–12,757) <0.0001
LVEF 26 (20–40) 25 (17–35) 29 (20–40) 30 (20–45) 0.0005
Cardiac troponin-I (pg/ml) 16.4 (9.2–31.6) 14.6 (8.1–28.1) 17.8 (10.0–31.9) 17.3 (9.5–36.2) 0.09
Time from presentation to randomization (h) 17.7 (8.1–22.6) 18.2 (9.1–22.0) 16.2 (7.2–22.5) 17.9 (7.3–23.1) 0.99
Ischemic etiology 60.0 50.2 66.4 63.9 0.0007
Beta-blockers 75.0 73.5 74.7 77.0 0.34
ACEi or ARB 64.3 64.6 68.2 60.1 0.26
MRA 24.2 28.2 24.3 20.3 0.026
Values are median (Q1 to Q3) or n (%). *p value from test of trend (Cochrane-Armitage trend test and Jonckheere-Terpstra trend tests).
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; KIM ¼ kidney injury molecule;
LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal prohormone brain natriuretic peptide.
TABLE 2 Impact of Nesiritide Therapy on Serial Changes in KIM-1 Levels
KIM-1 Levels (pg/ml)
Placebo
(n ¼ 436)
Nesiritide
(n ¼ 438) p Value
Baseline 366 (234 to 622) 388 (240 to 649) 0.22
48–72 h 368 (215 to 608) 395 (225 to 648) 0.58
30 days 353 (220 to 588) 411 (253 to 671) 0.028
Changes from baseline to 48–72 h 0.30 (58.4 to 66.7) 13.5 (71.7 to 37.3) 0.067
Changes from baseline to 30 days 4.40 (97.7 to 80) 17.3 (54.0 to 121.9) 0.0009
Values are median (Q1 to Q3).
Abbreviations as in Table 1.
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779for recurrent heart failure within 30 days of ran-
domization. Dyspnea response was analyzed as a
dichotomous variable identifying those in whom
dyspnea had moderately or markedly improved 6 to
24 h after being assigned randomly. Death and
worsening heart failure were assessed together as a
composite secondary endpoint and all events were
adjudicated through 180 days.
STATISTICAL ANALYSES. Baseline characteristics
and renal outcomes were presented as median (inter-
quartile range [IQR]) for continuous variables and as
percentage for categorical variables. The Jonckheere–
Terpstra and Cochran–Armitage trend tests were used
to assess the signiﬁcance of a trend across increasing
tertiles of KIM-1 for continuous and categorical vari-
ables, respectively. Double-sided p values 0.05 were
considered signiﬁcant. Circulating KIM-1 levels were
compared between patients randomly assigned to
placebo or nesiritide via the Wilcoxon rank-sum
test. Nonparametric linear correlates of other renal
biomarkers to KIM-1 levels were presented as
Spearman correlation coefﬁcients (r). The association
between KIM-1 and intermediate outcomes was per-
formed via logistic regression analyses for improve-
ment in dyspnea at 6 and 24 h, and death or worsening
heart failure in the hospital. After observing no trends
with time for the Schoenfeld residuals, the associationof KIM-1 and long-term outcomes was performed via
Cox proportional hazards models for the endpoints of
30-day mortality, 30-day mortality or worsening heart
failure, and 180-day mortality. For multivariable
analyses, we adjusted for covariates that have been
identiﬁed for the overall ASCEND-HF study popu-
lation, as described previously (6,22). The Kaplan–
Meier method was used to compare 180-day mor-
tality across groups. Differences across tertiles of
KIM-1 levels and across strata of median KIM-1 and
median cystatin C were determined by the log-rank
test. All statistical analyses were performed using
SAS software, version 9.3 (SAS Institute, Cary, North
Carolina).
TABLE 3 Correlation of Baseline KIM-1 With Other Baseline Indices of Renal Function*
KIM-1 Creatinine BUN Cystatin C eGFR†
KIM-1 — 0.26
(p < 0.0001)
0.29
(p < 0.0001)
0.38
(p < 0.0001)
0.33
(p < 0.0001)
Creatinine 0.26
(p < 0.0001)
— 0.69
(p < 0.0001)
0.70
(p < 0.0001)
0.89
(p < 0.0001)
BUN 0.29
(p < 0.0001)
0.69
(p < 0.0001)
— 0.66
(p < 0.0001)
0.74
(p < 0.0001)
Cystatin C 0.38
(p < 0.0001)
0.70
(p < 0.0001)
0.66
(p < 0.0001)
— 0.78
(p < 0.0001)
eGFR* 0.33
(p < 0.0001)
0.89
(p < 0.0001)
0.74
(p < 0.0001)
0.78
(p < 0.0001)
—
*Spearman correlation coefﬁcients. †eGFR estimated by the 4-variable Modiﬁcation of Diet in Renal Disease
equation.
eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in Table 1.
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780RESULTS
STUDY POPULATION. The median circulating KIM-1
level at baseline was 375.4 pg/ml (IQR: 237.0 to 633.1
pg/ml). Baseline characteristics stratiﬁed by baseline
circulating KIM-1 levels of this substudy cohort are
provided in Table 1. Higher circulating KIM-1 levels
were associated with older age, prevalent female sex,
prevalent diabetes mellitus, higher systolic blood
pressure and lower heart rate, prevalent atrial ﬁbril-
lation, higher left ventricular ejection fraction, pre-
valent ischemic heart failure etiology, and lower
mineralocorticoid receptor antagonist usage. In-
creasing baseline KIM-1 was also associated with
baseline markers of worse renal function and neuro-
hormonal activation, including higher blood urea
nitrogen, higher serum creatinine, and higher
N-terminal prohormone brain natriuretic peptide
levels. There was no association between baseline
KIM-1 and cardiac troponin-I levels.
SERIAL KIM-1 LEVELS. Of the 874 patients with
baseline KIM-1 levels, 706 had KIM-1 levels drawn at
48 to 72 h, and 661 had KIM-1 levels drawn at 30 days.
The median KIM-1 level at 48 to 72 h was 373.7 pg/ml
(IQR: 220.3 to 640.5 pg/ml) and at 30 days was
382.6 pg/ml (IQR: 236.5 to 638.0 pg/ml). Table 2TABLE 4 Renal Outcomes Stratiﬁed by Baseline KIM-1 Level
<278.3
24-h Dcreatinine (mmol/l) 0.0 (8.8 to 11.5)
24-h urine volume (ml) 2,980 (1,900 to 4,170)
48- to 72-h Dcystatin C >0.3 mg/l (%) 17.9
Dynamic renal function at 48 h (%) 19.6
Values are median (Q1 to Q3) or %. *p value from test of trend (Cochrane-Armitage tre
Abbreviations as in Table 1.demonstrates that there was a trend toward a
larger increase in KIM-1 levels from baseline to 48
to 72 h when stratiﬁed by treatment (nesiritide vs.
placebo) from randomization (13.5 pg/ml [IQR: 71.7
to 37.3 pg/ml] vs. 0.30 pg/ml [IQR: 58.4 to 66.7
pg/ml], respectively; p ¼ 0.067). However, this
relationship became evident by 30 days, because
the nesiritide arm demonstrated a greater increase
in KIM-1 levels compared with the placebo arm
(17.3 pg/ml [IQR: 54.0 to 121.9 pg/ml] vs. 4.40
pg/ml [IQR: 97.7 to 80.0 pg/ml], respectively;
p ¼ 0.0009).
RELATIONSHIP OF KIM-1 AND OTHER MEASURES
OF RENAL FUNCTION AND ITS IMPACT ON RENAL
OUTCOMES DURING HOSPITALIZATION. Baseline
KIM-1 levels moderately correlated to other markers of
renal function (Table 3), but were highly correlated to
follow-upKIM-1 levels at 48 to 72 h (Spearman r¼0.89;
p < 0.0001) and 30 days (Spearman r ¼ 0.82;
p < 0.0001). The relationship between increasing
baseline KIM-1 levels and renal outcomes during
treatment is shown in Table 4. Increasing baseline
KIM-1 was associated with a lesser 24-h urine volume
(p ¼ 0.019), greater creatinine increase at 24 h (p ¼
0.048), more dynamic renal function at 48 h
(deﬁned as either an increase or decrease in serum
creatinine of $0.3 mg/dl; p ¼ 0.0008), and a greater
incidence of worsening renal function (Dcystatin C
>0.3 mg/l) by 48 to 72 h (p < 0.0001). Subjects who
developed worsening renal function during decon-
gestive therapy demonstrated higher plasma KIM-1
levels at baseline and at 48 to 72 h (both p ¼
0.03), but not at 30 days (p ¼ 0.07) when compared
with those who did not experience worsening renal
function (Figure 1).
ASSOCIATION OF BASELINE AND FOLLOW-UP KIM-1
AND OUTCOMES. Kaplan–Meier estimates of survival
at 180 days are shown in Figure 2 for baseline and 30-
day KIM-1 tertiles. There were 25 deaths (2.9%) by 30
days and 100 deaths (11.6%) by 180 days. By 30 days,
there were 101 deaths or recurrent heart failureBaseline KIM-1 (pg/ml)
278.3–526.7 >526.7 p Value*
1.8 (8.8 to 14.0) 1.8 (8.8 to 17.7) 0.048
2,575 (1,700 to 3,500) 2,550 (1,810 to 3,730) 0.019
25.9 25.8 0.044
30.9 33.8 0.0008
nd test and Jonckheere-Terpstra trend tests).
FIGURE 1 KIM-1 Levels at Different Time Points
KIM-1 levels at different time points according to the development of worsening renal
function* by 72 h. *Deﬁned as a change in cystatin C >0.3 mg/l at 72 h from baseline.
KIM ¼ kidney injury molecule; WRF ¼ worsening renal function.
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781hospitalizations (11.7%). The association between
baseline, 48- to 72-h, and 30-day circulating KIM-1
levels and dyspnea scores and clinical outcomes is
shown in Table 5. In univariable analyses, higher
baseline, 48- to 72-h, and 30-day log-transformed
KIM-1 levels were only associated with 180-day mor-
tality (all p < 0.05), but not dyspnea or other clinical
outcomes. After multivariable adjustment for all of
the covariates in adjusted model 1, the association
between log-transformed KIM-1 levels and 180-day
mortality was weakly nonsigniﬁcant (p ¼ 0.053)
when measured at baseline, but remained signiﬁcant
when measured at 48 to 72 h and 30 days (both p <
0.05). Dyspnea and the other clinical outcomes
remained unassociated with log-transformed KIM-1.
When the multivariable adjustment included blood
urea nitrogen/creatinine (adjusted model 2), only
30-day log-transformed KIM-1 levels were associ-
ated with 180-day mortality (p ¼ 0.04). There was
no interaction with 30-day KIM-1 levels and nesiri-
tide treatment (p ¼ 0.89). Otherwise, none of the
previous associations persisted and there remained
no associations with log-transformed KIM-1 levels
and dyspnea or other clinical outcomes. When
stratifying by high or low KIM-1 levels (divided by
median baseline values) and high or low cystatin C
levels (divided by median baseline values), there
were signiﬁcantly different Kaplan–Meier estimates
of 180-day survival (Figure 3) (p < 0.0001); none-
theless, this seemed to be driven more by cystatin C
than KIM-1. Individually, there was a nonsigniﬁcant
trend toward lower survival for high versus low
KIM-1 (log-rank p ¼ 0.056) and a highly signiﬁcant
lower survival for high versus low cystatin C (log-
rank p < 0.0001).
DISCUSSION
There are several new ﬁndings from this analysis.
First, overall circulating KIM-1 levels did not ﬂuc-
tuate to a great extent from ADHF to post-discharge
follow-up (assuming a more stabilized state). Sec-
ond, circulating KIM-1 levels modestly track with
other biomarkers of renal function (serum creatinine,
blood urea nitrogen, and cystatin C), but were asso-
ciated with short-term adverse renal outcomes.
Third, even though they track with long-term mor-
tality in univariable comparison, circulating KIM-1
levels were not independently prognostic for either
intermediate or long-term clinical outcomes when
measured at either baseline or 48 to 72 h. Also,
higher baseline cystatin C levels stratiﬁed mortality
risk more than higher baseline KIM-1 levels. Last,
subjects randomly assigned to nesiritide had higher
FIGURE 2 Kaplan-Meier Estimates of 180-Day Survival According to
Baseline and 30-Day KIM-1 Levels
Kaplan-Meier estimates of 180-day survival according to (A) baseline KIM-1 levels
(tertile 1, <278.3 pg/ml; tertile 2, 278.3 to 526.7 pg/ml; and tertile 3, >526.7 pg/ml) and
(B) 30-day KIM-1 levels (tertile 1, <282.0 pg/ml; tertile 2, 282.0 to 530.1 pg/ml; and
tertile 3, >530.1 pg/ml). Abbreviations as in Figure 1.
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782levels of KIM-1 at 30 days than study subjects
randomly assigned to placebo, although the clinical
signiﬁcance of this observation is unclear because
there was no interaction with 30-day KIM-1 levels
and nesiritide treatment. Taken together, we con-
clude that circulating KIM-1 levels yield limited
incremental clinical or prognostic information dur-
ing the management of ADHF independent of more
traditional measures of renal function (creatinine
and blood urea nitrogen). The only inconsistent
ﬁnding was that 30-day follow-up KIM-1 levels were
associated independently with 180-day mortality.
This may reﬂect the relatively “stable” chronic na-
ture of 30-day clinical status in contrast with those
measured during ADHF admission.
Worsening renal function in patients with ADHF
is a well-described, strong predictor of adverseoutcomes (24–27). Consequently, successful treat-
ment of ADHF includes not only decongestion and
symptom alleviation, but also maintaining or pre-
serving renal function. Clinical trials for novel
therapies or treatments for both ADHF and chronic
heart failure commonly have worsening renal
function as a safety endpoint, or are aimed at pre-
serving renal function, although there has been
increasing scrutiny over the reliability of renal
indices as surrogate measures of cardiorenal dys-
function (28–31).
KIM-1 may be an early marker of cardiorenal syn-
drome (15), because it is highly expressed on
the surface of injured tubule epithelial cells and
transforms epithelial cells into phagocytic cells,
which clear apoptotic and necrotic cells after acute
tubular injury (11). As a result, urinary KIM-1 is a
highly speciﬁc marker for acute tubular injury and is
commonly increased in patients with heart failure
(10,17). However, less is known about plasma levels of
KIM-1. There are several reasons supporting its
detection in the plasma after acute tubular injury:
KIM-1 may be released directly into the interstitium
through loss of tubular permeability and back-leak of
contents into the circulation via breakdown of the
microvascular architecture of the endothelial cells
and basement membrane (32–34). Plasma KIM-1 levels
correlate well with urinary KIM-1 levels and are
associated with renal dysfunction (19). Consistent
with urinary KIM-1 levels, our ﬁnding that plasma
KIM-1 levels were only modestly correlated with
other renal indices (Table 3) may imply other renal
physiologic processes that are not reﬂected by more
traditional metrics of renal function (16). Further-
more, we observed that increased plasma KIM-1 at
baseline is associated with decreased diuresis and a
greater incidence of renal dysfunction (Table 4), and
is higher in subjects who developed worsening renal
function by 72 h (Figure 1), indicating that circul-
ating KIM-1 levels do reﬂect some degree of renal
insufﬁciency.
Although baseline urinary KIM-1 has been shown
to yield incremental prognostic information to esti-
mated glomerular ﬁltration in chronic heart failure,
data from patients with ADHF have not shown the
same association between elevated urinary KIM-1 and
poor prognosis (16–18). Our current ﬁndings with
circulating levels also demonstrated no incremental
beneﬁt of KIM-1 levels when measured in plasma
beyond more traditional markers of renal function
in ADHF. There may be several potential explana-
tions for this ﬁnding. First, altered central or renal
hemodynamics as a result of increased venous con-
gestion and/or decreased cardiac output may affect
TABLE 5 KIM-1 Levels and Intermediate- and Long-Term Outcomes
Endpoint
Unadjusted* Adjusted Model 1† Adjusted Model 2‡
OR/HR p Value OR/HR p Value OR/HR p Value
Baseline KIM-1 levels
Death at 30 days 1.15 0.55 1.10 0.73 0.88 0.68
Death/rehospitalization at 30 days 1.06 0.63 1.04 0.73 0.90 0.44
Death at 180 days 1.28 0.04 1.30 0.053 1.12 0.44
Improved dyspnea at 6 h 0.91 0.30 0.90 0.38 0.91 0.45
Improved dyspnea at 24 h 1.04 0.75 1.03 0.86 1.07 0.68
Death or worsening HF pre-discharge 1.40 0.07 1.37 0.11 1.07 0.75
48- to 72-h follow-up KIM-1 levels
Death at 30 days 1.17 0.56 1.08 0.81 0.82 0.54
Death/rehospitalization at 30 days 1.10 0.47 1.06 0.65 0.88 0.34
Death at 180 days 1.42 0.006 1.46 0.01 1.23 0.21
Improved dyspnea at 6 h 0.93 0.47 0.93 0.57 0.91 0.52
Improved dyspnea at 24 h 0.91 0.50 0.99 0.94 1.07 0.70
Death or worsening HF pre-discharge 1.19 0.39 1.07 0.76 0.75 0.25
30-day KIM-1 levels
Death at 180 days 1.60 0.002 1.75 0.002 1.49 0.04
*Unadjusted: only log-transformed KIM-1. †Adjusted model 1, log-transformed KIM-1 adjusted with covariates derived from the original ASCEND-HF population excluding
BUN/creatinine. ‡Adjusted model 2, log-transformed KIM-1 adjusted with covariates derived from the original ASCEND-HF population including BUN/creatinine.
HF ¼ heart failure; HR ¼ hazard ratio; OR ¼ odds ratio; other abbreviations as in Table 1.
FIGURE 3 Kaplan-Meier Estimates of 180-Day Survival According to
Median Baseline KIM-1 Levels
Kaplan-Meier estimates of 180-day survival according to median baseline KIM-1 levels
stratiﬁed by median baseline cystatin C (Cys-C) levels. There was a nonsigniﬁcant
trend toward lower survival for high versus low KIM-1 (log-rank p ¼ 0.056) and a
highly signiﬁcant lower survival for high versus low cystatin C (log-rank p < 0.0001).
KIM-1 median, 375.1 pg/ml; cystatin C median, 1.48 mg/l. Abbreviations as in Figure 1.
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783glomerular ﬁltration more than tubular function in
the kidneys. Second, although KIM-1 is a sensitive
marker for tubular injury resulting from nephrotoxic
medications, the degree of tubular injury may not be
as severe during ADHF, as indicated by previous
studies on urinary neutrophil gelatinase-associated
lipocalin, which is another marker of renal tubular
damage (35,36).
There was a trend of higher KIM-1 in the nesiritide
versus placebo groups, but there was a limited impact
on clinical outcomes between treatment groups, and
there was no interaction with 30-day KIM-1 levels
and nesiritide treatment. Therefore, using a surro-
gate marker of tubular injury without assessing
“hard” adverse outcomes remains a challenge.
STUDY LIMITATIONS. The results of this study must
be interpreted in light of various limitations inherent
to its design. First, the absence of overlap between
creatinine, cystatin C, and blood urea nitrogen values
in conjunction with the KIM-1 draws (48 to 72 h and
30 days of blood sampled and analyzed in the core
laboratory versus clinically collected creatinine and
blood urea nitrogen levels at baseline, 24 h, and at
the end of treatment) and the absence of available
urine output data past 24 h, limit our ability to assess
cardiorenal outcomes during the remainder of hos-
pitalization. Second, there was a paucity of data to
assess the additional contribution of other heartfailure pharmacotherapies on the incidence of
renal insufﬁciency or clinical outcomes. Finally,
although nesiritide use was associated with higher
follow-up KIM-1 levels, caution should be used in
interpreting these results, because this study was
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
preservation of renal function is paramount during the
clinical management of acute heart failure. Unlike
more commonplace measures of renal function, which
Grodin et al. J A C C : H E A R T F A I L U R E V O L . 3 , N O . 1 0 , 2 0 1 5
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784not appropriately powered to demonstrate such a
difference. Regardless, with carefully adjudicated
outcomes, our analysis suggests that there is little
role for measuring plasma KIM-1 and predicting
adverse clinical outcomes in ADHF, but does provide
insight into renal tubular damage in heart failure and
its prognostic implications.estimate glomerular ﬁltration (e.g., creatinine and
cystatin C), circulating KIM-1 levels are speciﬁc for
tubular injury. Although KIM-1 levels were associated
with worsening renal function estimated by traditional
measures, they were not associated independently
with clinical outcomes.
TRANSLATIONAL OUTLOOK: This analysis ques-
tions the prognostic implications of assessing tubular
injury in acute heart failure. However, the patho-
physiology of tubular injury in acute heart failure is
not well understood and the therapeutic implications
are unknown. Additional clinical and mechanistic
studies are needed to investigate these characteristics
for KIM-1 and other biomarkers of tubular injury.CONCLUSIONS
In our study cohort, circulating KIM-1 at baseline and
during hospitalization was not associated with
adverse clinical outcomes in ADHF after adjusting for
standard indices of kidney function. Nesiritide use
may be associated with a greater rise in circulating
KIM-1 levels, although its use did not correlate with
adverse clinical outcomes.
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